JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 153 filers reported holding JUNO THERAPEUTICS INC in Q2 2015. The put-call ratio across all filers is 2.17 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $17,288,000 | +18.8% | 378,195 | +16.6% | 0.01% | +7.7% |
| Q3 2017 | $14,552,000 | +80.3% | 324,374 | +20.2% | 0.01% | +62.5% |
| Q2 2017 | $8,069,000 | +26.7% | 269,956 | -6.0% | 0.01% | +33.3% |
| Q1 2017 | $6,371,000 | +25.5% | 287,104 | +6.6% | 0.01% | 0.0% |
| Q4 2016 | $5,078,000 | -29.5% | 269,346 | +12.2% | 0.01% | -25.0% |
| Q3 2016 | $7,204,000 | -20.1% | 240,040 | +2.4% | 0.01% | -27.3% |
| Q2 2016 | $9,013,000 | +11.2% | 234,448 | +10.2% | 0.01% | 0.0% |
| Q1 2016 | $8,104,000 | -0.1% | 212,737 | +15.3% | 0.01% | 0.0% |
| Q4 2015 | $8,113,000 | +23.5% | 184,508 | +14.3% | 0.01% | +10.0% |
| Q3 2015 | $6,569,000 | +117.4% | 161,440 | +184.9% | 0.01% | +150.0% |
| Q2 2015 | $3,022,000 | +10.4% | 56,663 | +25.6% | 0.00% | 0.0% |
| Q1 2015 | $2,737,000 | – | 45,113 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |